Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To print this article:
Existing subscribers please log in:
 
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 
 
 

Biogenerics: myth or reality?

The opportunities offered by biogenerics are by no means straightforward are providing fertile ground for (legal) interpretation.

Dr Enrico T Polastro, Arthur D Little Internationa (December 2001)

Keywords: biopharm, bioreactor, genetic engineering, microbial, cell culture, cell separation, genetics, genomics, biosensors, molecular biology, microbiological testing, microbiology, protein engineering, oligonucleotides, collaboration, biotech research, company news, events, biomedical, industry, government, life sciences, education, investor, publications, medicine, medical, genes, genetic, engineering, recombinant, cell therapy, microbiology, pharmacology, sequencing, bioengineering, chromosome, genetics, protein, CAT, galactosidase, NPT, immunofluorescense, antibody, chromatography, filtration, nucleotide, m13, lambda, instaprep, perfectprep, bigprep, PerfectRNA, subventions, Arthur D Little International

    View full article    |    Back to Industry Insight section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |